In vitro susceptibility of clinical isolates of Dipodascus capitatus
Abstract number: P1357
Cendejas E., Gómez-López A., Cuenca-Estrella M., Rodríguez-Tudela J.
Background:D. capitatus (teleomorph of Geotrichum capitatum), has been added to the lengthening list of opportunistic fungal pathogens that can cause fatal infections in inmunocompromised patients. In order to give any insight on the management of this emerging infection we have analysed the antifungal susceptibility profile of eight currently available antifungal agents against a collection of D.capitatus clinical isolates.
Methods: A total of 35 clinical strains of D. capitatus were included. The strains were recovered from different Spanish hospitals through a period of ten years, from 1996 to 2006, and identified by routine physiological tests. The susceptibility testing followed strictly the recommendations proposed by the Antifungal Susceptibility testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing for fermentative yeast, including some modifications to allow for automation of the method and to permit the incubation period to be shortened from 72 to 48 h The antifungal agents used in the study were as follow: Amphotericin B (AMB), flucytosine (5-FC), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), ravuconazole (RVC), posaconazole (POS) and caspofungin (CAS).
Results: All isolates produced clearly visible growth after 48 hours of incubation following the method described. A wide range of MICs was observed for AMB with values ranging between 0.06 and 32 mg/L. Tree strains (3/35, 8.6%) showed a AMB MIC 1 mg/L. Only one isolate was resistant in vitro to flucytosine (MIC > 32 mg/L). Fluconazole showed poor activity, with MIC 4 mg/L for most of the strains tested (97%). Among new azole compounds, ITC exhibited the best activity compared with VRC, RVC and POS (Geometric Mean of MICs, 0.17, 0.22, 0.23 and 0.19 respectively). On the other hand, CAS showed poor in vitro activity against most of the strains tested (GM 24.25 mg/L)
Conclusion: (1) Isolates of D. capitatus were in vitro susceptible to Amphotericin B, flucytosine and new azole agents, specially ITC. (2) The majority of D. capitatus tested were resistant to FLC.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|